Global AL Amyloidosis Therapeutics market size is predicted to grow from US$ 2500 million in 2025 to US$ 3874 million in 2031; it is expected to grow at a CAGR of 7.6% from 2025 to 2031. Get Access Now!

Global AL Amyloidosis Therapeutics Market Growth Status and Outlook 2025-2031

The global AL Amyloidosis Therapeutics market size is predicted to grow from US$ 2500 million in 2025 to US$ 3874 million in 2031; it is expected to grow at a CAGR of 7.6% from 2025 to 2031. The most common kind of systemic amyloidosis is the amyloid light chain (AL) amyloidosis, sometimes referred to as primary amyloidosis. Systemic light-chain (AL) amyloidosis was once thought to be an unstoppable deadly condition. The AL amyloidosis therapeutics market is driven by the increasing awareness of the disease and advances in medical research. AL amyloidosis is a rare and life-threatening condition caused by the deposition of abnormal proteins in tissues and organs. The rise in diagnostic capabilities and the growing understanding of the diseases pathophysiology have led to the development of targeted therapies, driving market growth. Moreover, the emergence of novel treatment options, such as monoclonal antibodies and proteasome inhibitors, has significantly improved patient outcomes. However, the market also faces challenges, including the rarity of the disease, making clinical trials and drug development more challenging. Additionally, the need for early and accurate diagnosis and the high cost of specialized therapies pose obstacles for both patients and healthcare systems. To succeed, companies must invest in research and development, collaborate with healthcare providers to improve disease awareness and diagnosis, and work towards making AL amyloidosis therapeutics more accessible and affordable for patients in need. LPI (LP Information) newest research report, the AL Amyloidosis Therapeutics Industry Forecast looks at past sales and reviews total world AL Amyloidosis Therapeutics sales in 2024, providing a comprehensive analysis by region and market sector of projected AL Amyloidosis Therapeutics sales for 2025 through 2031. With AL Amyloidosis Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world AL Amyloidosis Therapeutics industry. This Insight Report provides a comprehensive analysis of the global AL Amyloidosis Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on AL Amyloidosis Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global AL Amyloidosis Therapeutics market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for AL Amyloidosis Therapeutics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global AL Amyloidosis Therapeutics. This report presents a comprehensive overview, market shares, and growth opportunities of AL Amyloidosis Therapeutics market by product type, application, key players and key regions and countries. Segmentation by Type: &nbsp;&nbsp;&nbsp; Chemotherapy &nbsp;&nbsp;&nbsp; Supportive Care &nbsp;&nbsp;&nbsp; Surgery &nbsp;&nbsp;&nbsp; Stem Cell Transplant &nbsp;&nbsp;&nbsp; Targeted Therapy Segmentation by Application: &nbsp;&nbsp;&nbsp; Hospitals &nbsp;&nbsp;&nbsp; Clinics &nbsp;&nbsp;&nbsp; Ambulatory Service Centres &nbsp;&nbsp;&nbsp; Others This report also splits the market by region: &nbsp;&nbsp;&nbsp; Americas &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Canada &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mexico &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brazil &nbsp;&nbsp;&nbsp; APAC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; China &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Korea &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Southeast Asia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; India &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Australia &nbsp;&nbsp;&nbsp; Europe &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Germany &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; France &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Italy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russia &nbsp;&nbsp;&nbsp; Middle East & Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Egypt &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; South Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Israel &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turkey &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the companys coverage, product portfolio, its market penetration. &nbsp;&nbsp;&nbsp; Janssen Pharmaceutical &nbsp;&nbsp;&nbsp; Prothena &nbsp;&nbsp;&nbsp; Alexion Pharmaceuticals &nbsp;&nbsp;&nbsp; Oncopeptides AB &nbsp;&nbsp;&nbsp; Bristol-Myers Squibb &nbsp;&nbsp;&nbsp; GlaxoSmithKline Pharmaceuticals Ltd &nbsp;&nbsp;&nbsp; Eidos Therapeutics, Inc. &nbsp;&nbsp;&nbsp; Corino Therapeutics, Inc. &nbsp;&nbsp;&nbsp; Spectrum Pharmaceuticals, Inc. &nbsp;&nbsp;&nbsp; Pfizer

1 Scope of the Report &nbsp;1.1 Market Introduction &nbsp;1.2 Years Considered &nbsp;1.3 Research Objectives &nbsp;1.4 Market Research Methodology &nbsp;1.5 Research Process and Data Source &nbsp;1.6 Economic Indicators &nbsp;1.7 Currency Considered &nbsp;1.8 Market Estimation Caveats 2 Executive Summary &nbsp;2.1 World Market Overview &nbsp;2.1.1 Global AL Amyloidosis Therapeutics Market Size (2020-2031) &nbsp;2.1.2 AL Amyloidosis Therapeutics Market Size CAGR by Region (2020 VS 2024 VS 2031) &nbsp;2.1.3 World Current & Future Analysis for AL Amyloidosis Therapeutics by Country/Region (2020, 2024 & 2031) &nbsp;2.2 AL Amyloidosis Therapeutics Segment by Type &nbsp;2.2.1 Chemotherapy &nbsp;2.2.2 Supportive Care &nbsp;2.2.3 Surgery &nbsp;2.2.4 Stem Cell Transplant &nbsp;2.2.5 Targeted Therapy &nbsp;2.3 AL Amyloidosis Therapeutics Market Size by Type &nbsp;2.3.1 AL Amyloidosis Therapeutics Market Size CAGR by Type (2020 VS 2024 VS 2031) &nbsp;2.3.2 Global AL Amyloidosis Therapeutics Market Size Market Share by Type (2020-2025) &nbsp;2.4 AL Amyloidosis Therapeutics Segment by Application &nbsp;2.4.1 Hospitals &nbsp;2.4.2 Clinics &nbsp;2.4.3 Ambulatory Service Centres &nbsp;2.4.4 Others &nbsp;2.5 AL Amyloidosis Therapeutics Market Size by Application &nbsp;2.5.1 AL Amyloidosis Therapeutics Market Size CAGR by Application (2020 VS 2024 VS 2031) &nbsp;2.5.2 Global AL Amyloidosis Therapeutics Market Size Market Share by Application (2020-2025) 3 AL Amyloidosis Therapeutics Market Size by Player &nbsp;3.1 AL Amyloidosis Therapeutics Market Size Market Share by Player &nbsp;3.1.1 Global AL Amyloidosis Therapeutics Revenue by Player (2020-2025) &nbsp;3.1.2 Global AL Amyloidosis Therapeutics Revenue Market Share by Player (2020-2025) &nbsp;3.2 Global AL Amyloidosis Therapeutics Key Players Head office and Products Offered &nbsp;3.3 Market Concentration Rate Analysis &nbsp;3.3.1 Competition Landscape Analysis &nbsp;3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025) &nbsp;3.4 New Products and Potential Entrants &nbsp;3.5 Mergers & Acquisitions, Expansion 4 AL Amyloidosis Therapeutics by Region &nbsp;4.1 AL Amyloidosis Therapeutics Market Size by Region (2020-2025) &nbsp;4.2 Global AL Amyloidosis Therapeutics Annual Revenue by Country/Region (2020-2025) &nbsp;4.3 Americas AL Amyloidosis Therapeutics Market Size Growth (2020-2025) &nbsp;4.4 APAC AL Amyloidosis Therapeutics Market Size Growth (2020-2025) &nbsp;4.5 Europe AL Amyloidosis Therapeutics Market Size Growth (2020-2025) &nbsp;4.6 Middle East & Africa AL Amyloidosis Therapeutics Market Size Growth (2020-2025) 5 Americas &nbsp;5.1 Americas AL Amyloidosis Therapeutics Market Size by Country (2020-2025) &nbsp;5.2 Americas AL Amyloidosis Therapeutics Market Size by Type (2020-2025) &nbsp;5.3 Americas AL Amyloidosis Therapeutics Market Size by Application (2020-2025) &nbsp;5.4 United States &nbsp;5.5 Canada &nbsp;5.6 Mexico &nbsp;5.7 Brazil 6 APAC &nbsp;6.1 APAC AL Amyloidosis Therapeutics Market Size by Region (2020-2025) &nbsp;6.2 APAC AL Amyloidosis Therapeutics Market Size by Type (2020-2025) &nbsp;6.3 APAC AL Amyloidosis Therapeutics Market Size by Application (2020-2025) &nbsp;6.4 China &nbsp;6.5 Japan &nbsp;6.6 South Korea &nbsp;6.7 Southeast Asia &nbsp;6.8 India &nbsp;6.9 Australia 7 Europe &nbsp;7.1 Europe AL Amyloidosis Therapeutics Market Size by Country (2020-2025) &nbsp;7.2 Europe AL Amyloidosis Therapeutics Market Size by Type (2020-2025) &nbsp;7.3 Europe AL Amyloidosis Therapeutics Market Size by Application (2020-2025) &nbsp;7.4 Germany &nbsp;7.5 France &nbsp;7.6 UK &nbsp;7.7 Italy &nbsp;7.8 Russia 8 Middle East & Africa &nbsp;8.1 Middle East & Africa AL Amyloidosis Therapeutics by Region (2020-2025) &nbsp;8.2 Middle East & Africa AL Amyloidosis Therapeutics Market Size by Type (2020-2025) &nbsp;8.3 Middle East & Africa AL Amyloidosis Therapeutics Market Size by Application (2020-2025) &nbsp;8.4 Egypt &nbsp;8.5 South Africa &nbsp;8.6 Israel &nbsp;8.7 Turkey &nbsp;8.8 GCC Countries 9 Market Drivers, Challenges and Trends &nbsp;9.1 Market Drivers & Growth Opportunities &nbsp;9.2 Market Challenges & Risks &nbsp;9.3 Industry Trends 10 Global AL Amyloidosis Therapeutics Market Forecast &nbsp;10.1 Global AL Amyloidosis Therapeutics Forecast by Region (2026-2031) &nbsp;10.1.1 Global AL Amyloidosis Therapeutics Forecast by Region (2026-2031) &nbsp;10.1.2 Americas AL Amyloidosis Therapeutics Forecast &nbsp;10.1.3 APAC AL Amyloidosis Therapeutics Forecast &nbsp;10.1.4 Europe AL Amyloidosis Therapeutics Forecast &nbsp;10.1.5 Middle East & Africa AL Amyloidosis Therapeutics Forecast &nbsp;10.2 Americas AL Amyloidosis Therapeutics Forecast by Country (2026-2031) &nbsp;10.2.1 United States Market AL Amyloidosis Therapeutics Forecast &nbsp;10.2.2 Canada Market AL Amyloidosis Therapeutics Forecast &nbsp;10.2.3 Mexico Market AL Amyloidosis Therapeutics Forecast &nbsp;10.2.4 Brazil Market AL Amyloidosis Therapeutics Forecast &nbsp;10.3 APAC AL Amyloidosis Therapeutics Forecast by Region (2026-2031) &nbsp;10.3.1 China AL Amyloidosis Therapeutics Market Forecast &nbsp;10.3.2 Japan Market AL Amyloidosis Therapeutics Forecast &nbsp;10.3.3 Korea Market AL Amyloidosis Therapeutics Forecast &nbsp;10.3.4 Southeast Asia Market AL Amyloidosis Therapeutics Forecast &nbsp;10.3.5 India Market AL Amyloidosis Therapeutics Forecast &nbsp;10.3.6 Australia Market AL Amyloidosis Therapeutics Forecast &nbsp;10.4 Europe AL Amyloidosis Therapeutics Forecast by Country (2026-2031) &nbsp;10.4.1 Germany Market AL Amyloidosis Therapeutics Forecast &nbsp;10.4.2 France Market AL Amyloidosis Therapeutics Forecast &nbsp;10.4.3 UK Market AL Amyloidosis Therapeutics Forecast &nbsp;10.4.4 Italy Market AL Amyloidosis Therapeutics Forecast &nbsp;10.4.5 Russia Market AL Amyloidosis Therapeutics Forecast &nbsp;10.5 Middle East & Africa AL Amyloidosis Therapeutics Forecast by Region (2026-2031) &nbsp;10.5.1 Egypt Market AL Amyloidosis Therapeutics Forecast &nbsp;10.5.2 South Africa Market AL Amyloidosis Therapeutics Forecast &nbsp;10.5.3 Israel Market AL Amyloidosis Therapeutics Forecast &nbsp;10.5.4 Turkey Market AL Amyloidosis Therapeutics Forecast &nbsp;10.6 Global AL Amyloidosis Therapeutics Forecast by Type (2026-2031) &nbsp;10.7 Global AL Amyloidosis Therapeutics Forecast by Application (2026-2031) &nbsp;10.7.1 GCC Countries Market AL Amyloidosis Therapeutics Forecast 11 Key Players Analysis &nbsp;11.1 Janssen Pharmaceutical &nbsp;11.1.1 Janssen Pharmaceutical Company Information &nbsp;11.1.2 Janssen Pharmaceutical AL Amyloidosis Therapeutics Product Offered &nbsp;11.1.3 Janssen Pharmaceutical AL Amyloidosis Therapeutics Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.1.4 Janssen Pharmaceutical Main Business Overview &nbsp;11.1.5 Janssen Pharmaceutical Latest Developments &nbsp;11.2 Prothena &nbsp;11.2.1 Prothena Company Information &nbsp;11.2.2 Prothena AL Amyloidosis Therapeutics Product Offered &nbsp;11.2.3 Prothena AL Amyloidosis Therapeutics Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.2.4 Prothena Main Business Overview &nbsp;11.2.5 Prothena Latest Developments &nbsp;11.3 Alexion Pharmaceuticals &nbsp;11.3.1 Alexion Pharmaceuticals Company Information &nbsp;11.3.2 Alexion Pharmaceuticals AL Amyloidosis Therapeutics Product Offered &nbsp;11.3.3 Alexion Pharmaceuticals AL Amyloidosis Therapeutics Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.3.4 Alexion Pharmaceuticals Main Business Overview &nbsp;11.3.5 Alexion Pharmaceuticals Latest Developments &nbsp;11.4 Oncopeptides AB &nbsp;11.4.1 Oncopeptides AB Company Information &nbsp;11.4.2 Oncopeptides AB AL Amyloidosis Therapeutics Product Offered &nbsp;11.4.3 Oncopeptides AB AL Amyloidosis Therapeutics Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.4.4 Oncopeptides AB Main Business Overview &nbsp;11.4.5 Oncopeptides AB Latest Developments &nbsp;11.5 Bristol-Myers Squibb &nbsp;11.5.1 Bristol-Myers Squibb Company Information &nbsp;11.5.2 Bristol-Myers Squibb AL Amyloidosis Therapeutics Product Offered &nbsp;11.5.3 Bristol-Myers Squibb AL Amyloidosis Therapeutics Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.5.4 Bristol-Myers Squibb Main Business Overview &nbsp;11.5.5 Bristol-Myers Squibb Latest Developments &nbsp;11.6 GlaxoSmithKline Pharmaceuticals Ltd &nbsp;11.6.1 GlaxoSmithKline Pharmaceuticals Ltd Company Information &nbsp;11.6.2 GlaxoSmithKline Pharmaceuticals Ltd AL Amyloidosis Therapeutics Product Offered &nbsp;11.6.3 GlaxoSmithKline Pharmaceuticals Ltd AL Amyloidosis Therapeutics Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.6.4 GlaxoSmithKline Pharmaceuticals Ltd Main Business Overview &nbsp;11.6.5 GlaxoSmithKline Pharmaceuticals Ltd Latest Developments &nbsp;11.7 Eidos Therapeutics, Inc. &nbsp;11.7.1 Eidos Therapeutics, Inc. Company Information &nbsp;11.7.2 Eidos Therapeutics, Inc. AL Amyloidosis Therapeutics Product Offered &nbsp;11.7.3 Eidos Therapeutics, Inc. AL Amyloidosis Therapeutics Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.7.4 Eidos Therapeutics, Inc. Main Business Overview &nbsp;11.7.5 Eidos Therapeutics, Inc. Latest Developments &nbsp;11.8 Corino Therapeutics, Inc. &nbsp;11.8.1 Corino Therapeutics, Inc. Company Information &nbsp;11.8.2 Corino Therapeutics, Inc. AL Amyloidosis Therapeutics Product Offered &nbsp;11.8.3 Corino Therapeutics, Inc. AL Amyloidosis Therapeutics Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.8.4 Corino Therapeutics, Inc. Main Business Overview &nbsp;11.8.5 Corino Therapeutics, Inc. Latest Developments &nbsp;11.9 Spectrum Pharmaceuticals, Inc. &nbsp;11.9.1 Spectrum Pharmaceuticals, Inc. Company Information &nbsp;11.9.2 Spectrum Pharmaceuticals, Inc. AL Amyloidosis Therapeutics Product Offered &nbsp;11.9.3 Spectrum Pharmaceuticals, Inc. AL Amyloidosis Therapeutics Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.9.4 Spectrum Pharmaceuticals, Inc. Main Business Overview &nbsp;11.9.5 Spectrum Pharmaceuticals, Inc. Latest Developments &nbsp;11.10 Pfizer &nbsp;11.10.1 Pfizer Company Information &nbsp;11.10.2 Pfizer AL Amyloidosis Therapeutics Product Offered &nbsp;11.10.3 Pfizer AL Amyloidosis Therapeutics Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.10.4 Pfizer Main Business Overview &nbsp;11.10.5 Pfizer Latest Developments 12 Research Findings and Conclusion

Report	Global AL Amyloidosis Therapeutics Market Growth (Status and Outlook) 2025-2031
Selected License	Multi ID: LPI35834

Buyer Information

Order Summary